Menopause in 2004: "Hormone replacement therapy" is not what it used to be anymore;Ménopause en 2004: Le «traitement hormonal substitutif» n'est plus ce qu'il était

Revue de Medecine Interne

Volumn 25, Issue 11, 2004, Pages 806-815

  Azoulay, C ^a,b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Breast cancer; Cardiovascular disease; Diphosphonate; Hormone replacement therapy; Menopause; Osteoporosis; Phytoestrogen; Raloxifene; Tibolone

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CONJUGATED ESTROGEN; COUMESTAN DERIVATIVE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; MEDROXYPROGESTERONE; PHYTOESTROGEN; RALOXIFENE; TIBOLONE; UNCLASSIFIED DRUG; EQUILIN;

BRAIN FUNCTION; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CANCER; COLORECTAL CANCER; DEMENTIA; ENDOMETRIUM CANCER; FRAGILITY FRACTURE; HEART INFARCTION; HEART PROTECTION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PHLEBITIS; POSTMENOPAUSE OSTEOPOROSIS; REIMBURSEMENT; REVIEW; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; HOT FLUSH; LIFESTYLE; MENOPAUSE; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS; EQUILIN; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; LIFE STYLE; MEDROXYPROGESTERONE; MENOPAUSE; MYOCARDIAL INFARCTION; PHYTOESTROGENS; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 14344249180     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2004.07.003     Document Type: Short Survey

References (62)

1. Godeau P. L'interniste et la ḿnopause Reprod. Hum. Horm. 13 2000 203 209
2. AFSSAPS:: communiqué de presse du 08:aôt 2003. Traitement hormonal substitutif et risque de cancer du sein.
3. Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women J Clin Endocrinol Metab 88 2003 4031 4042
4. Humphrey L.L., Chan B.K., and Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease Ann Intern Med 137 2002 273 284
5. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., and Vittighoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
6. Writing group for the PEPI trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199 208
7. Writing group for the Women's Health Initiative investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial JAMA 288 2002 321 333
8. Speroff L. WHI trial: it's time to be critical! Am J Obstet Gynecol 189 2003 620
9. Speroff L. The impact of the Women's Health Initiative on clinical practice J Soc Gynecol Investig 9 2002 251 253
10. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., and Lasser N.L. Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
11. Esprit Team Estrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial Lancet 360 2002 2001 2008
12. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., and Mahrer P.R. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women N Engl J Med 349 2003 535 545
13. Bongard V., Ferrieres J., Ruidavets J.B., Amouyel P., Arveiler D., and Bingham A. Transdermal estrogen replacement therapy and plasma lipids in 693:French women Maturitas 30 1998 265 272
14. Galand-Portier M.B., De Lignìres B., and Kuttenn F. Impact cardiovasculaire du THS:: une mise au point apr̀s HERS, WEST et WHI Gyńcol Obst́t pratique 158 2003 1 6
15. Scarabin P.Y. L'hormonoth́rapie substitutive de la ḿnopause apporte-t-elle un b́ńfice cardiovasculaire:? Rev Ḿd Int 24 2003 216 217
16. The Women's Health Initiative Steering Committee Effects of conjugated equine oestrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
17. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke N Engl J Med 345 2001 1243 1249
18. Miller J., Chan B.K.S., and Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systemic review and meta-analysis for the U.S. preventive services task force Ann Intern Med 136 2002 680 690
19. Scarabin P.Y., Oger E., Plu-Bureau G. Estrogen ThromboEmbolism Risk study Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
20. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., and Lane D. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women-The Women's Health Initiative randomized trial JAMA 289 2003 3243 3253
21. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the million women study Lancet 362 2003 419 427
22. Speroff L. The million women study and breast cancer Maturitas 46 2003 1 6
23. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., and Pettinger M. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial JAMA 290 2003 1739 1748
24. Hulley S.B., and Grady D. The WHI estrogen-alone trial. Do things look any better? JAMA 291 2004 1769 1771
25. Ahlborg H.G., Johnell O., Turner C.H., Rannevik G., and Karlsson M.K. Bone loss and bone size after menopause N Engl J Med 349 2003 327 334
26. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., and LaCroix A.Z. Effects of estrogen plus progestin on risk of fracture and bone mineral density-The Women's Health Initiative randomized trial JAMA 290 2003 1729 1738
27. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., and Ockene J.K. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study (WHIMS) JAMA 289 2003 2651 2662
28. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., and Manson J.E. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2663 2672
29. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., and Baird A. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial JAMA 289 2003 2673 2684
30. Hays J., Ockene J.K., Brunner R.L., Kotchen J.M., Manson J.E., and Patterson R.E. Effects of estrogen plus progestin on health-related quality of life N Engl J Med 348 19 2003 May 8 1839 1854
31. Reid R.L. Hormone therapy: the Women's Health Initiative has caused confusion and concern Fertil Steril 80 2003 491 493
32. Bouchard P. Traitement hormonal substitutif de la ḿnopause:: les suites de la WHI, HERS II, et autres ḿta-analyses:: le r̂ve est-il briś:? Ŕf Gyńcol Obstet 9 2002 11 13
33. Anaes/Afssaps Traitements hormonaux substitutifs de la ḿnopause -- rapport d'orientation 11:mai 2004
34. Collins J.A. How does the WHI study alter the risk-benefit ratio of HT? Fertil Steril 80 2003 19 26
35. Strickler R.C. Women's Health Initiative results: a glass more empty than full Fertil Steril 80 2003 488 490
36. Neves-e-Castro M., Samsioe G., Doren M., and O. Skouby S. European Menopause & Andropause Society. Results from WHI and HERS II-implications for women and the prescriber of HRT Maturitas 42 2002 255 258
37. Kim C., and Kwok Y.S. Decision analysis of hormone replacement therapy after the Women's Health Initiative Am J Obstet Gynecol 189 2003 1228 1233
38. Ettinger B., Grady D., Tosteson A.N., Pressman A., and Macer J.L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy Obstet Gynecol 102 2003 1225 1232
39. Hendrix S.L. Menopausal hormone therapy informed consent Am J Obstet Gynecol 189 2003 S31 S32 discussion S32-6
40. Graesslin O., Martin-Morille C., Bory J.P., and Quereux C. Alternatives au traitement hormonal substitutif Encycl Ḿd Chir 2002 8 (Éditions Scientifiques et Ḿdicales Elsevier SAS, Paris), Gyńcologie, 38-A-30
41. Davis S.R. Menopause: new therapies Med J Aust 178 2003 634 637
42. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action J Steroid Biochem Mol Biol 76 2001 231 238
43. Palacios S. Tibolone: what does tissue specific activity mean? Maturitas 37 2001 159 165
44. Berning B., Bennink H.J., and Fauser B.C. Tibolone and its effects on bone: a review Climacteric 4 2001 120 136
45. Rymer J. Why tibolone is different? Rev Gynecol Pract 2 2002 35 39
46. Stahlberg C., Pedersen A.T., Lynge E., Andersen Z.J., Keiding N., and Hundrup Y.A. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe Int J Cancer 109 2004 721 727
47. Moore R.A. Livial: a review of clinical studies Br J Obstet Gynaecol 106 1999 1 21
48. Jamin C., Poncelet C., and Madelenat P. Tibolone Presse Med 31 2002 1314 1322
49. Modelska K., and Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials J Clin Endocrinol Metab 87 2002 16 23
50. Acog practice bulletin Selective estrogen receptor modulators Int J Gynecol Obstet 79 2002 289 298
51. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice N Engl J Med 348 2003 618 629
52. Maudelonde T. Les modulateurs ślectifs des ŕcepteurs aux estrog̀nes. Ḿcanisme d'action Reprod. Hum. Horm. 13 2000 4 15
53. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., and Adachi J. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis Endocr Rev 23 2002 524 528
54. Delmas P.D. Effets osseux des SERM Reprod. Hum. Horm. 13 2000 16 20
55. Fontana A., and Delmas P.D. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis Endocrinol Metab Clin North Am 32 2003 219 232
56. Rozenbaum H. Le raloxif̀ne. Principales proprít́s, effets sur les organes cibles (extraosseux), toĺrance clinique Reprod. Hum. Horm. 13 2000 21 32
57. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., and Gennari C. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 2002 3609 3617
58. Barrett-Connor E., Ensrud K.E., Harper K., Mason T.M., Sashegyi A., and Krueger K.A. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2:diabetes Clin Ther 25 2003 919 930
59. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., and Hoszowski K. MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 2002 847 857
60. Dodin S., Blanchet C., and Marc I. Phytoestrog̀nes chez la femme ḿnopauśe Ḿdecine & Sciences 19 2003 1030 1037
61. Fitzpatrick L.A. Soy isoflavones: hope or hype? Maturitas 44 2003 S21 S29
62. Wuttke W., Jarry H., Westphalen S., Christoffel V., and Seidlova-Wuttke D. Phytoestrogens for hormone replacement therapy? J Steroid Biochem Mol Biol 83 2002 133 147